

Digital Experience

13-15 October 2021

ECTRIMS
EUROPEAN COMMITTEE FOR TREATMENT
AND RESEARCH IN MULTIPLE SCLEROSIS

Educational Session Programme

**Track 1 Clinical diagnosis, imaging
and biomarkers of MS**

Track 2 Therapeutics in MS

Track 3 Pathology

Track 4 MS differential diagnosis

Each track includes 6 sessions. Two sessions will take place during the ECTRIMS Congress (13-15 October 2021), followed by 4 sessions that take place in the weeks after the congress. Tickets can be bought for an entire track or just specific sessions.

Wednesday, 13 October 2021

12:00 – 13:00

Educational Session 1: MOGAD: differentiating from MS and AQP4 NMOSD

Track 4

Chair: Jacqueline Palace (Oxford, United Kingdom)
Chair: Brenda Banwell (Philadelphia, United States)

12:00

Introduction by chairs

12:05

Clinical features and neuroimaging in MOGAD: Differentiation from MS and NMOSD
Speaker: Jacqueline Palace (Oxford, United Kingdom)

12:20

Application and limitation of MOG antibody assays
Speaker: Fabienne Brilot (Sydney, Australia)

12:35

Treatment strategy and future outlook in MOGAD
Speaker: Brenda Banwell (Philadelphia, United States)

12:50

Live Discussion

12:00 – 13:00

Educational Session 2: Treatment of relapsing-remitting MS

Track 2

Chair: Frauke Zipp (Mainz, Germany)
Chair: Maria Trojano (Bari, Italy)

12:00

Introduction by chairs

12:05

Should every relapsing MS patient be treated?
Speaker: Jaume Sastre-Garriga (Barcelona, Spain)

12:20

Switching treatments: when and how?
Speaker: Frauke Zipp (Mainz, Germany)

12:35

Is there a place for induction treatment?

Educational Session Programme

Speaker: Maria Trojano (Bari, Italy)

12:50

Live Discussion

13:15 – 14:15

Educational Session 3: Treatment of progressive MS

Chair: Xavier Montalban (Barcelona, Spain)

Chair: Jeremy Chataway (London, United Kingdom)

Track 2

13:15

Introduction by chairs

13:20

Which progressive patient should be treated?

Speaker: Xavier Montalban (Barcelona, Spain)

13:35

How to monitor treatment responses in progressive patients?

Speaker: Daniel Ontaneda (Cleveland, United States)

13:50

Future treatment options for progressive MS

Speaker: Jeremy Chataway (London, United Kingdom)

14:05

Live Discussion

13:15 – 14:15

Educational Session 4: Diagnosis of MS

Chair: Georgina Arrambide (Barcelona, Spain)

Chair: Johannes Lorscheider (Basel, Switzerland)

Track 1

13:15

Introduction by chairs

13:20

The MS diagnostic criteria in clinical practice

Speaker: Georgina Arrambide (Barcelona, Spain)

13:35

When does progression start?

Speaker: Johannes Lorscheider (Basel, Switzerland)

13:50

Red flags and extreme presentation of MS

Speaker: Pierre Labauge (Montpellier, France)

14:05

Live Discussion

Educational Session Programme

Thursday, 14 October 2021

12:00 – 13:00	Educational Session 5: Pathology of MS Chair: Roberta Magliozzi (Verona, Italy) Chair: Hans Lassmann (Wien, Austria)	Track 3
12:00	Introduction by chairs	
12:05	Inflammatory reaction within the CNS of multiple sclerosis patients: mechanisms and potential triggers Speaker: Inge Huitinga (Amsterdam, Netherlands)	
12:20	Meningeal inflammation Speaker: Roberta Magliozzi (Verona, Italy)	
12:35	The pathology of multiple sclerosis and MOG antibody associated inflammatory demyelinating disease: similarities and differences Speaker: Hans Lassmann (Wien, Austria)	
12:50	Live Discussion	

15:00 – 16:00	Educational Session 6: Infections and MS Chair: Thomas Berger (Vienna, Austria) Chair: Renaud Du Pasquier (Lausanne, Switzerland)	Track 3
15:00	Introduction by chairs	
15:05	COVID-19 pandemic: multiple sclerosis patients under disease-modifying therapies Speaker: Thomas Berger (Vienna, Austria)	
15:20	The risk of infection among patients treated with disease-modifying therapies: factors to consider Speaker: Anna Fogdell-Hahn (Stockholm, Sweden)	
15:35	Opportunistic infections under disease-modifying therapies Speaker: Renaud Du Pasquier (Lausanne, Switzerland)	
15:50	Live Discussion	

Educational Session Programme

Friday, 15 October 2021

12:00 – 13:00

Educational Session 7: Early stages of MS

Chair: Russell Dale (Sydney, Australia)

Chair: Christine Lebrun-Frenay (Nice, France)

Track 1

12:00

Introduction by chairs

12:05

When does the disease start? MS Prodrome

Speaker: Ruth Ann Marrie (Winnipeg, Canada)

12:20

The radiologically isolated syndrome (RIS), is it already MS?

Speaker: Christine Lebrun-Frenay (Nice, France)

12:35

How could paediatric MS shed light on early MS?

Speaker: Russell Dale (Sydney, Australia)

12:50

Live Discussion

15:00 – 16:00

Educational Session 8: Beyond MS: Paraneoplastic syndromes, iatrogenic demyelination and autoimmune encephalitis

Chair: Josep Dalmau (Barcelona, Spain)

Chair: Reinhard Hohlfeld (Munich, Germany)

Track 4

15:00

Introduction by chairs

15:05

A practical update: Diagnosis and management of paraneoplastic and autoimmune encephalitis

Speaker: Josep Dalmau (Barcelona, Spain)

15:20

CNS Demyelination complicating immunotherapies: a rising spectrum

Speaker: Reinhard Hohlfeld (Munich, Germany)

Educational Session Programme

- 15:35 **Rare but paradigmatic inflammatory CNS disorders: Rasmussen, SUSAC, CLIPPERS, Narcolepsy**
Speaker: Alexandre Prat (Montreal, Canada)
- 15:50 **Live Discussion**

Friday, 29 October 2021

-
- 15:00 – 16:00 **Educational Session 9: A closer and quantitative look on in vivo MS pathology (MAGNIMS)** **Track 1**
Chair: Maria Assunta Rocca (Milan, Italy)
Chair: Cristina Granziera (Basel, Switzerland)
- 15:00 **Introduction by chairs**
- 15:05 **Imaging myelin damage**
Speaker: Maria Assunta Rocca (Milan, Italy)
- 15:20 **Imaging axonal damage**
Speaker: Cristina Granziera (Basel, Switzerland)
- 16:35 **Imaging MS lesion heterogeneity with susceptibility MRI**
Speaker: Daniel S. Reich (Bethesda, United States)
- 15:50 **Live Discussion**
-
- 15:00 – 16:00 **Educational Session 10: Specific aspects of MS treatment** **Track 2**
Chair: Sandra Vukusic (Lyon, France)
Chair: Clemens Warnke (Cologne, Germany)
- 15:00 **Introduction by chairs**
- 15:05 **DMTs in women planning or during pregnancy**
Speaker: Sandra Vukusic (Lyon, France)
- 15:20 **DMTs in elderly patients**
Speaker: Clemens Warnke (Cologne, Germany)

Educational Session Programme

- 15:35 **Stopping DMTs**
Speaker: Gabriel Bsteh (Vienna, Austria)
- 15:50 **Live Discussion**

16:15– 17:15 **Educational Session 11:ECTRIMS/EANM teaching course on molecular imaging**

Track 1

Chair: Bruno Stankoff (Paris, France)
Chair: Laura Airas (Turku, Finland)

- 16:15 **Introduction by chairs**
- 16:20 **Molecular imaging of the neuro-inflammatory component in MS**
Speaker: Laura Airas (Turku, Finland)
- 16:35 **Metabolic imaging in MS**
Speaker: Matilde Inglese (Genoa, Italy)
- 16:50 **Imaging myelin content change: PET or MRI?**
Speaker: Bruno Stankoff (Paris, France)
- 17:05 **Live Discussion**

16:15 – 17:15 **Educational Session 12: Symptomatic treatment of MS**

Track 2

Chair: Jalesh Panicker (London, United Kingdom)
Chair: Frank Weber (Cham, Germany)

- 16:15 **Introduction by chairs**
- 16:20 **Neurourology**
Speaker: Jalesh Panicker (London, United Kingdom)
- 16:35 **Spasticity**
Speaker: Frank Weber (Cham, Germany)

Educational Session Programme

- 16:50 **Neuropathic pain**
Speaker: Xavier Moisset (Clermont-Ferrand, France)
- 17:05 **Live Discussion**

Friday, 12 November

-
- 15:00 – 16:00 **Educational Session 13: Targeting progression and promotion of functional tissue recovery in the CSN** **Track 3**
Chair: Tanja Kuhlmann (Münster, Germany)
Chair: Martin Kerschensteiner (Munich, Germany)
- 15:00 **Introduction by chairs**
- 15:05 **Reasons for impaired remyelination in multiple sclerosis: previous concepts revisited**
Speaker: Tanja Kuhlmann (Münster, Germany)
- 15:20 **Neuroplasticity: its relevance for multiple sclerosis**
Speaker: Martin Kerschensteiner (Munich, Germany)
- 15:35 **Lessons from recent and ongoing treatment trials in progressive MS**
Speaker: Robert J. Fox (Cleveland, United States)
- 15:50 **Live Discussion**
-
- 15:00 – 16:00 **Educational Session 14: Insights in neuropathology and diagnosis of NMOSD** **Track 4**
Chair: Christine Stadelmann-Nessler (Göttingen, Germany)
Chair: Romain Marignier (Lyon, France)
- 15:00 **Introduction by chairs**

Educational Session Programme

- 15:05 **Neuropathology underlying NMOSD: Are AQP-4 antibody positive and negative cases one entity?**
Speaker: Christine Stadelmann-Nessler (Göttingen, Germany)
- 15:20 **Diagnosis of NMOSD**
Speaker: Brian Weinschenker (Rochester, United States)
- 15:35 **Clinical spectrum of NMOSD: Common and rare manifestations**
Speaker: Romain Marignier (Lyon, France)
- 15:50 **Live Discussion**

16:15 – 17:15 **Educational Session 15: Immunology of MS**

Chair: Mireia Sospedra Ramos (Zurich, Switzerland)
Chair: Marco Prinz (Freiburg, Germany)

Track 3

- 16:15 **Introduction by chairs**
- 16:20 **B cells and antibodies: the role of promoting inflammatory CNS demyelination**
Speaker: Markus Reindl (Innsbruck, Austria)
- 16:35 **T cells in multiple sclerosis: novel insights in immunopathogenesis**
Speaker: Mireia Sospedra Ramos (Zurich, Switzerland)
- 16:50 **Innate immune cells in MS**
Speaker: Martin Diebold (Freiburg, Germany)
- 17:05 **Live Discussion**

16:15 – 17:15 **Educational Session 16: Old and new players in the treatment of NMOSD**

Chair: Kazuo Fujihara (Sendai, Japan)
Chair: Tania Kümpfel (Munich, Germany)

Track 4

- 16:15 **Introduction by chairs**
- 16:20 **Treatment targets in NMOSD: A pathophysiological view**

Educational Session Programme

	Speaker: Kazuo Fujihara (Sendai, Japan)
16:35	Considerations for clinical trial design in rare diseases such as NMOSD Speaker: Sean Pittock (Rochester, United States)
16:50	Current standard of care and new emerging treatments in NMOSD Speaker: Tania Kümpfel (Munich, Germany)
17:05	Live Discussion

Friday, 26 November

15:00 – 16:00	Educational Session 17: Biomarkers in MS Chair: Jens Kuhle (Basel, Switzerland) Chair: Charlotte Teunissen (Amsterdam, Netherlands)	Track 1
15:00	Introduction by chairs	
15:05	NfL for prognostic and therapeutic follow up of patients with MS Speaker: Jens Kuhle (Basel, Switzerland)	
15:20	Other blood biomarkers in MS Speaker: Fredrik Piehl (Stockholm, Sweden)	
15:35	CSF biomarkers in MS Speaker: Charlotte Teunissen (Amsterdam, Netherlands)	
15:50	Live Discussion	
15:00 – 16:00	Educational Session 18: Statistic evaluation of clinical and observational trials	Track 2

Educational Session Programme

Chair: Maria Pia Sormani (Genoa, Italy)
Chair: Florian Deisenhammer (Innsbruck, Austria)

15:00	Introduction by chairs
15:05	Interpreting Propensity Score adjusted studies Speaker: Maria Pia Sormani (Genoa, Italy)
15:20	Methods to analyse relapses and MRI lesions Speaker: Brian Healy (Boston, United States)
15:35	Statistical significance and clinical relevance Speaker: Florian Deisenhammer (Innsbruck, Austria)
15:50	Live Discussion

16:15 – 17:15

Educational Session 19: Visual outcomes in MS and NMOSD

Track 1

Chair: Letizia Leocani (Milan, Italy)
Chair: Angela Vidal-Jordana (Barcelona, Spain)

16:15	Introduction by chairs
16:20	Visual evoked potentials in MS and NMOSD Speaker: Letizia Leocani (Milan, Italy)
16:35	OCT in MS and NMOSD Speaker: Angela Vidal-Jordana (Barcelona, Spain)
16:50	Functional and structural MR imaging of the visual system in MS and NMOSD Speaker: Friedemann Paul (Berlin, Germany)
17:05	Live Discussion

Educational Session Programme

16:15 – 17:15

Educational Session 20: Specific aspects of MS rehabilitation

Chair: Jennifer Freeman (Plymouth, United Kingdom)

Chair: Peter Feys (Hasselt, Belgium)

Track 2

16:15

Introduction by chairs

16:20

Rehabilitation in progressive MS

Speaker: Jennifer Freeman (Plymouth, United Kingdom)

16:35

Assistive technologies/devices and robotics

Speaker: Peter Feys (Hasselt, Belgium)

16:50

Managing cognitive dysfunction

Speaker: Aurélie Ruet (Bordeaux, France)

17:05

Live Discussion

Educational Session Programme

Friday, 10 December

15:00 – 16:00	Educational Session 21: Animal models of MS Chair: Jennifer Gommerman (Toronto, United States) Chair: Roland Liblau (Toulouse, France)	Track 3
15:00	Introduction by chairs	
15:05	Phenotype and function of leukocytes in brain inflammation: discovery of new druggable pathways Speaker: Katerina Akassoglou (San Francisco, United States)	
15:20	The regulation of neuroinflammation: from animal models to humans Speaker: Jennifer Gommerman (Toronto, United States)	
15:35	Treatment of multiple sclerosis: what can we learn from animal models Speaker: Roland Liblau (Toulouse, France)	
15:50	Live Discussion	

15:00 – 16:00	Educational Session 22: From typical to atypical demyelination – the role of MRI in identifying MS and characterising its variants (MAGNIMS/ECTRIMS session) Chair: Christian Enzinger (Graz, Austria) Chair: Olga Ciccarelli (London, United Kingdom)	Track 4
15:00	Introduction by chairs	
15:05	Brain MRI findings suggestive of demyelination but atypical for MS Speaker: Christian Enzinger (Graz, Austria)	
15:30	Spinal cord MRI findings atypical for MS Speaker: Olga Ciccarelli (London, United Kingdom)	
16:00	New MRI techniques to characterise MS variants Speaker: Frederik Barkhof (Amsterdam, Netherlands)	
15:50	Live Discussion	

Educational Session Programme

16:15 – 17:15	Educational Session 23: Immunological MOAs of novel MS DMTs Chair: Eva Kubala Havrdová (Prague, Czech Republic) Chair: Amit Bar-Or (Philadelphia, United States)	Track 3
16:15	Introduction by chairs	
16:20	What does not work in multiple sclerosis: lessons from failed clinical trials Speaker: Eva Kubala Havrdová (Prague, Czech Republic)	
16:35	Treatment of progressive multiple sclerosis: potential new targets Speaker: V. Wee Yong (Calgary, Canada)	
16:50	MOA of BTK inhibitors Speaker: Amit Bar-Or (Philadelphia, United States)	
17:05	Live Discussion	
<hr/>		
16:15 – 17:15	Educational Session 24: Autoimmune demyelinating CNS diseases beside NMOSD and MOGAD Chair: Samia Khoury (Beirut, Lebanon) Chair: Yael Hacohen (London, United Kingdom)	Track 4
16:15	Introduction by chairs	
16:20	Clinical and neuroimaging features in rare CNS demyelinating diseases and systemic autoimmune diseases with CNS involvement Speaker: Dean M Wingerchuk (Scottsdale, United States)	
16:35	How useful are biomarkers for differential diagnosis in CNS demyelination? ACE, ANA & co and their limitation Speaker: Samia Khoury (Beirut, Lebanon)	
16:50	Post-infectious and post-vaccination CNS demyelination Speaker: Yael Hacohen (London, United Kingdom)	
17:05	Live Discussion	